Study archive · AI simulation with synthetic data · Human validation pending

Initial review — P01

Reviewer: Jordan Ellis, fictional regional sales director at a hypothetical midmarket healthcare-software vendor; AI role simulation, not an actual stakeholder.

Read order: R73, then R14, then the supplied review schema. No clarification received; no linked sources opened.

R73

Next action: The sales operations manager should coordinate with opportunity owners to reconcile all 47 supplied open Orthopedic Surgery opportunities against the 2026-08-31 scenario date, checking source-system stages and close dates and documenting owner support. Return the confirmed open exposure and unresolved rows to Jordan Ellis before using the $6,272,200 supplied ACV in planning. All 47 opportunities are overdue by 45 to 315 days, so the supplied open total needs validation. Account needs require a separate check before any commercial recommendation; this step authorizes no CRM changes or outreach.

Can state action without clarification: Yes.

Clarification required: No. There are no questions required to understand the handoff or next action.

Missing evidence in the handoff:

• The handoff does not include the opportunity-level roster, identifiers, owner attestations, or supporting stage and close-date evidence; source links are supplied as pointers.
• The extract capture timestamp, source provenance verification, and reconciled account-level exposure remain unverified, as the brief acknowledges.

Apparent interpretation errors: None identified from the handoff alone.

Business questions for the next check:

• Which of the 47 opportunities have owner-supported open stages as of the scenario date?
• What close dates can owners substantiate, and what explains the overdue dates?
• What confirmed open ACV remains after review, and which rows or amounts remain unresolved?
• When was the supplied sales extract captured, and does it represent the scenario date closely enough for the proposed planning use?
• What account-specific evidence would support a separate assessment of software needs?

Source or format cues:

• Uses a structured handoff with metric lists, limits, open question, named reviewer role, requested check, draft status, and GitHub source links.
• Mentions an app artifact, local extract reconciliation, and a coordinator-captured export; the source list includes receipt.json as well as mart.csv and a metric certification log.
• These are visible provenance and format cues only; linked sources were not opened and no condition was inferred.

Confidence: High in understanding the next action; source accuracy remains unverified.

R14

Next action: The sales operations manager should have opportunity owners review all 53 supplied open Dermatology opportunities against the 2026-08-31 scenario date, confirming source-system stages and close dates and the evidence for retaining each opportunity in open pipeline. Return a reconciled open-ACV total to Jordan Ellis before planning use. All 53 opportunities are overdue by 25 to 291 days, so the supplied $4,579,800 ACV cannot yet be relied on for planning. Separately validate account needs before proposing account action; this check authorizes no CRM changes or outreach.

Can state action without clarification: Yes.

Clarification required: No. There are no questions required to understand the handoff or next action.

Missing evidence in the handoff:

• The handoff does not include opportunity-level identifiers, owners, or evidence substantiating open stages and close dates; source links are supplied as pointers.
• The extract capture timestamp, source validation, reconciled exposure, account linkage, and account-specific needs evidence are absent or explicitly pending.

Apparent interpretation errors: None identified from the handoff alone.

Business questions for the next check:

• Which of the 53 opportunities still have evidence supporting an open stage as of the scenario date?
• What close dates can owners substantiate, and what explains the overdue dates?
• What is the reconciled open-ACV total, and what uncertainty remains in that total?
• When was the sales extract captured, and is its timing appropriate for the proposed planning use?
• What account linkage and discovery evidence would support a separate assessment of software needs?

Source or format cues:

• Uses the same structured section pattern of metric lists, limits, open question, next reviewer, requested check, draft status, and GitHub source links.
• Explicitly describes payment as service-weighted; its source list includes mart.csv and a metric certification log but no receipt.json link.
• These are visible provenance and format cues only; linked sources were not opened and no condition was inferred.

Confidence: High in understanding the next action; source accuracy remains unverified.

Comparison notes

Initial review completed in the assigned order, R73 then R14, using only those briefs and the supplied schema, before any clarification. Both make the next investigation and responsible role understandable. The overdue count, scenario date, owner review, source-system stage/close-date checks, and required return to Jordan establish a concrete next step. R73 explicitly requests unresolved rows with confirmed exposure; R14 explicitly requests a reconciled total. Both separate synthetic reimbursement comparisons from software ACV and limit planning and commercial interpretation. Neither supplies the row-level evidence needed to resolve the investigation, but that is work for the requested next check rather than a clarification barrier. No specific interpretation error is apparent from the handoffs alone. Confidence concerns understanding the next action, not source accuracy or the validity of the exposure totals.